Emerging as a potential therapeutic approach, Retatrutide is generating significant attention within the weight loss community. This groundbreaking dual agonist targeting two GIP and GLP-1 targets demonstrates significant effectiveness in preclinical research and current phase 2 human testing. Early data suggest substantial fat loss and improvement